查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535649

大肠直肠癌治疗市场规模 - 按治疗（免疫疗法、化疗）、癌症类型（大肠直肠腺癌、胃肠道类癌）、治疗提供者（医院、专科诊所）和预测，2024 - 2032 年

Colorectal Cancer Therapeutics Market Size - By Therapy (Immunotherapy, Chemotherapy), Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors), Treatment Provider (Hospitals, Specialty Clinics) & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 114 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在该领域不断增加的研发力度的推动下，2024 年至 2032 年间，全球大肠直肠癌治疗市场的复合年增长率将超过 4.6%。由于大肠直肠癌仍然是全球癌症相关死亡的主要原因，因此迫切需要有效的治疗方法。製药公司和研究机构正在大力投资开发新疗法，包括标靶疗法、免疫疗法和个人化医疗方法。

例如，2024 年 7 月，一种新型药物组合显示出透过非常规方法抑制肿瘤的潜力。这种策略不是抑制肿瘤细胞分裂（这是大多数标准治疗的重点），而是涉及过度激活肿瘤细胞内的致癌信号以诱导压力。这种创新方法将在荷兰的结直肠癌患者中进行测试。

此外，对结直肠癌遗传和分子机制的日益了解正在为创新治疗铺平道路。政府对癌症研究的倡议和资助也在加速这些发展方面发挥着至关重要的作用。因此，在更有效、更有针对性和个性化的治疗选择的承诺的推动下，结直肠癌治疗市场有望显着增长，从而提高患者的生存率和生活品质。

整个大肠直肠癌治疗产业根据治疗、癌症类型、治疗提供者和地区进行分类。

从治疗来看，化疗领域的结直肠癌治疗市场份额从2024 年到2032 年将实现令人称讚的复合年增长率。癌细胞的功效，仍是治疗大肠直肠癌的基石。它能够解决疾病的各个阶段，特别是与其他治疗方式结合使用时，确保了其持续的相关性。对有效化疗方案的持续需求推动了对新药物製剂和改进的给药方法的需求。随着研究的进展，将化疗与新疗法相结合旨在提高患者的治疗效果并维持大肠癌治疗的市场成长。

就癌症类型而言，从 2024 年到 2032 年，胃肠道类癌肿瘤将出现显着增长。针对类癌独特生物学机制的创新疗法对于改善患者预后至关重要。胜肽受体放射性核素疗法（PRRT）和专为神经内分泌肿瘤设计的标靶药物的进展正在获得关注。随着医疗保健提供者寻求有效的解决方案来管理这些复杂的肿瘤，大肠直肠癌治疗的这个利基但关键的领域正在推动市场成长。

2024年至2032年，欧洲大肠癌治疗市场将呈现显着的复合年增长率。该地区强大的医疗基础设施支持创新疗法的采用，包括标靶治疗、免疫疗法和个人化医疗。此外，研发方面的大量投资以及政府资助和监管支持正在加速新治疗方案的推出。随着欧洲国家努力改善患者的治疗效果和存活率，对尖端大肠直肠癌疗法的需求不断扩大。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 大肠直肠癌的发生率和盛行率不断增加
      • 大肠直肠癌治疗的技术进步
      • 提高认识和早期发现
    • 产业陷阱与挑战
      • 与治疗相关的高成本和副作用
  • 成长潜力分析
  • 管道分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按疗法分类，2021 - 2032 年

  • 主要趋势
  • 化疗
  • 免疫疗法
  • 其他疗法

第 6 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 大肠直肠腺癌
  • 胃肠道类癌
  • 其他癌症类型

第 7 章：市场估计与预测：按治疗提供者划分，2021 - 2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 癌症研究机构

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celleron Therapeutics
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • TAIHO PHARMACEUTICAL CO., LTD
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
简介目录
Product Code: 9808

Global Colorectal Cancer Therapeutics Market will witness over 4.6% CAGR between 2024 and 2032, driven by rising research and development efforts in the field. As colorectal cancer remains a leading cause of cancer-related deaths globally, there is an urgent need for effective treatments. Pharmaceutical companies and research institutions are investing heavily in developing novel therapies, including targeted therapies, immunotherapies, and personalized medicine approaches.

For instance, in July 2024, a novel drug combination showed the potential to suppress tumors through an unconventional approach. Rather than inhibiting tumor cell division, which is the focus of most standard treatments, this strategy involved hyperactivating oncogenic signaling within the tumor cells to induce stress. This innovative approach was set to be tested in colorectal cancer patients in the Netherlands.

Additionally, the increasing understanding of the genetic and molecular mechanisms underlying colorectal cancer is paving the way for innovative treatments. Government initiatives and funding for cancer research are also playing a crucial role in accelerating these developments. As a result, the colorectal cancer therapeutics market is poised for significant growth, driven by the promise of more effective, targeted, and personalized treatment options that improve patient survival rates and quality of life.

The overall Colorectal Cancer Therapeutics Industry is classified based on the therapy, cancer type, treatment provider, and region.

Based on therapy, the colorectal cancer therapeutics market share from the chemotherapy segment will register a commendable CAGR from 2024 to 2032. Despite advancements in targeted and immunotherapy, chemotherapy remains a cornerstone in managing colorectal cancer due to its efficacy in targeting rapidly dividing cancer cells. Its ability to address various stages of the disease, especially when combined with other therapeutic modalities, ensures its ongoing relevance. The persistent need for effective chemotherapy regimens drives demand for new drug formulations and improved delivery methods. As research progresses, integrating chemotherapy with novel therapies aims to enhance patient outcomes and sustain market growth in colorectal cancer therapeutics.

In terms of cancer type, the gastrointestinal carcinoid tumors segment will witness appreciable growth from 2024 to 2032. These tumors, though rare, present unique treatment challenges that drive demand for specialized therapeutic options. Innovative therapies targeting the distinct biological mechanisms of carcinoid tumors are essential for improving patient outcomes. Advances in peptide receptor radionuclide therapy (PRRT) and targeted agents specifically designed for neuroendocrine tumors are gaining traction. This niche but critical area of colorectal cancer treatment is propelling market growth as healthcare providers seek effective solutions for managing these complex tumors.

Europe colorectal cancer therapeutics market will exhibit a notable CAGR from 2024 to 2032. Europe's aging population and increasing incidence of colorectal cancer necessitate effective treatment options, fueling market growth. The region's robust healthcare infrastructure supports the adoption of innovative therapies, including targeted treatments, immunotherapies, and personalized medicine. Additionally, significant investments in research and development, along with government funding and regulatory support, are accelerating the availability of new therapeutic options. As European countries strive to improve patient outcomes and survival rates, the demand for cutting-edge colorectal cancer therapies continues to expand.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence and prevalence of colorectal cancer
      • 3.2.1.2 Technological advancements in colorectal cancer therapeutics
      • 3.2.1.3 Increased awareness and early detection
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost and side effects associated with therapies
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Chemotherapy
  • 5.3 Immunotherapy
  • 5.4 Other therapies

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Colorectal adenocarcinoma
  • 6.3 Gastrointestinal carcinoid tumors
  • 6.4 Other cancer types

Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Amgen Inc.
  • 9.2 Bayer AG
  • 9.3 Bristol-Myers Squibb Company
  • 9.4 Celleron Therapeutics
  • 9.5 Eli Lilly and Company
  • 9.6 F. Hoffmann-La Roche Ltd.
  • 9.7 Genentech, Inc.
  • 9.8 Novartis AG
  • 9.9 Pfizer Inc.
  • 9.10 Sanofi S.A.
  • 9.11 Sumitomo Pharma Co., Ltd.
  • 9.12 Regeneron Pharmaceuticals, Inc.
  • 9.13 TAIHO PHARMACEUTICAL CO., LTD
  • 9.14 Takeda Pharmaceutical Company Limited
  • 9.15 Teva Pharmaceutical Industries Ltd.